Indegene Ltd (INDGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Indegene Ltd (INDGN) has a cash flow conversion efficiency ratio of 0.071x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs2.03 Billion ≈ $21.93 Million USD) by net assets (Rs28.66 Billion ≈ $309.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See INDGN equity financing ratio to measure how much of total assets are equity-financed.
Indegene Ltd - Cash Flow Conversion Efficiency Trend (2020–2026)
This chart illustrates how Indegene Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check INDGN cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Indegene Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Indegene Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Xianglu Tungsten Co Ltd
SHE:002842
|
-0.016x |
|
J & J Snack Foods Corp
NASDAQ:JJSF
|
0.018x |
|
Harrow Health Inc
NASDAQ:HROW
|
-0.317x |
|
HIAG Immobilien Holding AG
SW:HIAG
|
0.015x |
|
Babcock & Wilcox Enterprises Inc
NYSE:BW
|
-0.103x |
|
Arcelik AS
IS:ARCLK
|
-0.210x |
|
Qisda Corp
TW:2352
|
-0.072x |
|
Grupo Nacional Provincial S.A.B
MX:GNP
|
-0.024x |
Annual Cash Flow Conversion Efficiency for Indegene Ltd (2020–2026)
The table below shows the annual cash flow conversion efficiency of Indegene Ltd from 2020 to 2026. For the full company profile with market capitalisation and key ratios, see INDGN market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs31.39 Billion ≈ $339.44 Million |
Rs6.63 Billion ≈ $71.74 Million |
0.211x | +25.10% |
| 2025-03-31 | Rs26.16 Billion ≈ $282.87 Million |
Rs4.42 Billion ≈ $47.79 Million |
0.169x | -52.44% |
| 2024-03-31 | Rs14.29 Billion ≈ $154.55 Million |
Rs5.08 Billion ≈ $54.91 Million |
0.355x | +190.20% |
| 2023-03-31 | Rs10.64 Billion ≈ $115.04 Million |
Rs1.30 Billion ≈ $14.08 Million |
0.122x | -68.52% |
| 2022-03-31 | Rs7.64 Billion ≈ $82.61 Million |
Rs2.97 Billion ≈ $32.12 Million |
0.389x | -24.71% |
| 2021-03-31 | Rs3.33 Billion ≈ $36.02 Million |
Rs1.72 Billion ≈ $18.60 Million |
0.516x | +136.17% |
| 2020-03-31 | Rs-155.98 Million ≈ $-1.69 Million |
Rs222.73 Million ≈ $2.41 Million |
-1.428x | -- |
About Indegene Ltd
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It al… Read more